Anna Lorino

Anna Lorino is a seasoned Key Account Manager with extensive experience in the biotechnology and pharmaceutical industries. Currently at Geron Corporation, Anna is responsible for launching the first telomerase inhibitor RYTELO (Imetelstat) for low to intermediate-1 risk MDS with anemia. Previously, Anna held a similar role at CTI BioPharma, where significant contributions were made to the launch of VONJO in Myelofibrosis and the promotion of Doptelet for ITP, which included educating on disease states and managing market access promotional activities. Additional roles at Incyte, Celgene, and Novartis reinforced Anna's expertise in oncology, with pivotal launches and promotions of several key medications. Anna holds a Bachelor of Science degree in Family Studies from the University of Maryland.